Orasure Technologies (EP3) Q2 2026 Earnings Report

The call presents a cautiously positive picture: the company delivered sequential revenue growth (9.7%), segment recoveries (Diagnostics +14.7% and SMS +9.0% sequentially), margin expansion (+120 bps GAAP gross margin) and achieved important regulatory milestones (Colli‑Pee FDA clearance and Ebola 2.0 EUA). The primary setback is the withdrawal and delay of the IntelliQ CT/NG FDA submission, alongside a non‑GAAP operating loss ($14.7M) and negative operating cash flow (‑$9.9M) this quarter. Strong cash ($161M), zero debt, insourcing and cost discipline, and clear launch plans temper the impact of the IntelliQ delay and one‑time G&A items; management reiterates revenue growth for 2026 and expects operating cash flow breakeven entering 2027.

OraSure guided Q3 revenue of $29.5 million to $32.5 million with gross margin expected to be similar to Q2 (Q2 GAAP gross margin 43.5% and non‑GAAP gross margin 44.2%), reiterating full‑year 2026 revenue growth and a target of operating cash‑flow breakeven entering 2027; for context Q2 revenue was $30.6 million (up 9.7% sequentially) with Diagnostics $19.4 million (up 14.7% seq.) and SMS $9.9 million (up 9% seq.), Q2 operating cash flow was negative $9.9 million, GAAP operating income was $5.4 million (non‑GAAP operating loss $14.7 million), R&D was $9.4 million, S&M $6.6 million, G&A $14.4 million, non‑cash stock comp $2.3 million, D&A $2.4 million; balance sheet and capital notes included $161 million cash, zero debt, $2 million of share repurchases in Q2 (647k shares), $22 million returned year‑to‑date (7.7M shares, ~10% of shares; ~55% of a $40M authorization), a pause on buybacks to preserve flexibility for Colli‑Pee and Ebola 2.0 launch investments, an expected decline in G&A as nonrecurring items wind down, and a reduced contingent consideration liability tied to the IntelliQ resubmission plan.